Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Weiz – page 20

435 clinical trials in Weiz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Weiz at a glance
435
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

435 trials in Weiz

Open in trial search

Neurodermatitis

Not recruiting

Study on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Systemic scleroderma

Not recruiting

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fipaxalparant
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Ovarian cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Astrazeneca AB

Study on Long-Term Safety of Cendakimab for Adults and Adolescents with Eosinophilic Esophagitis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cendakimab
  • Sponsor:Celgene International II S.a.r.l.

Dermatitis atopic

Not recruiting

Study of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Astrazeneca AB

Systemic scleroderma

Not recruiting

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fipaxalparant
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not recruiting

Study of anifrolumab effectiveness compared to placebo in adults aged 18-70 with systemic sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Neurodermatitis

Not recruiting

Study on the Effectiveness and Safety of Ruxolitinib Cream for Patients with Prurigo Nodularis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Systemic scleroderma

Not recruiting

Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Weiz

What the registry says about research in the country

01 Breast Cancer Research

Clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer, investigating innovative therapeutic approaches for patients with high recurrence risk.

  • Node-positive breast cancer treatment
  • Endocrine therapy optimization
  • Early-stage breast cancer management

Research aims to improve disease-free survival rates through targeted therapeutic interventions.

02 Endocrine Therapy Studies

Investigating the effectiveness of elacestrant compared to standard endocrine treatments for breast cancer patients, with a focus on improving long-term outcomes.

  • Comparative treatment efficacy
  • Invasive cancer-free survival
  • Gender-inclusive research

Studies evaluate novel therapeutic approaches for both women and men with hormone-sensitive breast cancer.

03 Advanced Treatment Protocols

Evaluation of palbociclib in combination with standard endocrine therapy, exploring enhanced treatment strategies for early-stage breast cancer.

  • Combination therapy assessment
  • Long-term treatment outcomes
  • Risk reduction strategies

Research focuses on improving standard treatment protocols through innovative drug combinations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.